Impact of cemiplimab treatment duration on clinical outcomes in advanced cutaneous squamous cell carcinoma Domenico MallardoFrancesca SparanoPaolo Antonio Ascierto Research Open access 08 June 2024 Article: 160
Efficacy and safety of immune checkpoint inhibitors in solid tumor patients combined with chronic coronary syndromes or its risk factor: a nationwide multicenter cohort study Chao LiuYuli RuanYanqiao Zhang Research Open access 08 June 2024 Article: 159
A novel liver-function-indicators-based prognosis signature for patients with hepatocellular carcinoma treated with anti-programmed cell death-1 therapy Zehao ZhengJie MeiRongping Guo Research Open access 04 June 2024 Article: 158
MB2033, an anti-PD-L1 × IL-2 variant fusion protein, demonstrates robust anti-tumor efficacy with minimal peripheral toxicity Young Jin ParkSuna KimHa Hyung Kim Research Open access 04 June 2024 Article: 157
Comprehensive analysis of the relationship between ubiquitin-specific protease 21 (USP21) and prognosis, tumor microenvironment infiltration, and therapy response in colorectal cancer Haihang NieYali YuJun Fang Research Open access 04 June 2024 Article: 156
Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis Yueying ChenHedong HanTangfeng Lv Review Open access 04 June 2024 Article: 155
Combinational zimberelimab plus lenvatinib and chemotherapy for alpha-fetoprotein elevated, advanced gastric cancer patients (AFPGC): a phase 1 dose-escalation study Ting DengFeixue WangYi Ba Research Open access 04 June 2024 Article: 154
Integration of deep learning and habitat radiomics for predicting the response to immunotherapy in NSCLC patients Weimin CaiiXiao WuJunkai Chen Research Open access 04 June 2024 Article: 153
Two nomograms constructed for predicting the efficacy and prognosis of advanced non‑small cell lung cancer patients treated with anti‑PD‑1 inhibitors based on the absolute counts of lymphocyte subsets Aqing LiuGuan ZhangJianchun Yu Research Open access 04 June 2024 Article: 152
Inhibition of glycolysis enhances the efficacy of immunotherapy via PDK-mediated upregulation of PD-L1 Ruizhi ZhangGan MaoWei Li Research Open access 04 June 2024 Article: 151
Identification of an HLA-A*11:01-restricted neoepitope of mutant PIK3CA and its specific T cell receptors for cancer immunotherapy targeting hotspot driver mutations Meiying ShenSiyin ChenAishun Jin Research Open access 04 June 2024 Article: 150
Analysis of PD-L1 promoter methylation combined with immunogenic context in pancreatic ductal adenocarcinoma Xinyuan ChenShuangni YuXianlong Chen Research Open access 04 June 2024 Article: 149
Combination of STING agonist with anti-vascular RGD-(KLAKLAK)2 peptide as a novel anti-tumor therapy Justyna CzaplaAlina DrzyzgaRyszard Smolarczyk Research Open access 04 June 2024 Article: 148
SIRPG expression positively associates with an inflamed tumor microenvironment and response to PD-1 blockade Libo LuoMinlin JiangChuan Xu Research Open access 04 June 2024 Article: 147
Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study Tomoko KobayashiShintaro IwamaHiroshi Arima Research Open access 04 June 2024 Article: 146
The biological roles of CD47 in ovarian cancer progression Linan XingZhao WangJianhua Qian Review Open access 04 June 2024 Article: 145
Clinical outcomes and biomarker exploration of first-line PD-1 inhibitors plus chemotherapy in patients with low PD-L1-expressing of gastric or gastroesophageal junction adenocarcinoma Yu-Ting SunShi-Xun LuMiao-Zhen Qiu Research Open access 04 June 2024 Article: 144
USP47 deficiency in mice modulates tumor infiltrating immune cells and enhances antitumor immune responses in prostate cancer Qian-Lan WangShun-Yuan LuHong-Xin Zhang Research Open access 04 June 2024 Article: 143
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations Lorena IncorvaiaFernando Sabino Marques MonteiroMatteo Santoni Research Open access 04 June 2024 Article: 142
Prognostic value of genomic mutation signature associated with immune microenvironment in southern Chinese patients with esophageal squamous cell carcinoma Yue ZhouLi ChuZhengfei Zhu Research Open access 04 June 2024 Article: 141
Oligo-residual disease in PD-1/PD-L1 inhibitor-treated metastatic non-small cell lung cancer: incidence, pattern of failure, and clinical value of local consolidative therapy Jinmeng ZhangJie GaoZhengfei Zhu Research Open access 04 June 2024 Article: 140
Evaluation of the clinical application value of cytokine expression profiles in the differential diagnosis of prostate cancer Rongfa ChenLinna LiuXunjun Yang Research Open access 04 June 2024 Article: 139
Enhanced abscopal anti-tumor response via a triple combination of thermal ablation, IL-21, and PD-1 inhibition therapy Shaoxian WuHongwei JiangJingting Jiang Research Open access 04 June 2024 Article: 138
Rocaglamide promotes infiltration and differentiation of T cells and coordinates with PD-1 inhibitor to overcome checkpoint resistance in multiple tumor models Jiaojiao LuoWanyi NgChao Yao Research Open access 04 June 2024 Article: 137
The VISTA/VSIG3/PSGL-1 axis: crosstalk between immune effector cells and cancer cells in invasive ductal breast carcinoma Mateusz OlbromskiMonika MrozowskaHanna Romanowicz Research Open access 04 June 2024 Article: 136
The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients Yutaka ShimazuJunya KandaMasayuki Hino Research Open access 17 May 2024 Article: 135
The later-line efficacy and safety of immune checkpoint inhibitors plus anlotinib in EGFR-mutant patients with EGFR-TKI-resistant NSCLC: a single-center retrospective study Xiaoyan YinXinchao LiuXiangjiao Meng Research Open access 17 May 2024 Article: 134
Effect of radiochemotherapy on peripheral immune response in glioblastoma Léa HampeSusy DaumoineMarion Thibaudin Research Open access 16 May 2024 Article: 133
The optimal threshold of PD-L1 combined positive score to predict the benefit of PD-1 antibody plus chemotherapy for patients with HER2-negative gastric adenocarcinoma: a meta-analysis Ji-Bin LiMing-Yu LaiMiao-Zhen Qiu Research Open access 16 May 2024 Article: 132
GGT5: a potential immunotherapy response inhibitor in gastric cancer by modulating GSH metabolism and sustaining memory CD8+ T cell infiltration Wenjing ZhaoZiwei LiangJiannan Yao Research Open access 15 May 2024 Article: 131
circATAD2 mitigates CD8+ T cells antitumor immune surveillance in breast cancer via IGF2BP3/m6A/PD-L1 manner Zhiling ZhangWenjie HuoJie Li Research Open access 15 May 2024 Article: 130
Evaluation of the antitumor effect of neoantigen peptide vaccines derived from the translatome of lung cancer Fenbao LianHaitao YangBaosong Xie Research Open access 14 May 2024 Article: 129
Codonopsis pilosula-derived glycopeptide dCP1 promotes the polarization of tumor-associated macrophage from M2-like to M1 phenotype Hongxu LiuMaojin YaoJiaoyan Ren Research Open access 14 May 2024 Article: 128
Epigenetic silencing of LDHB promotes hepatocellular carcinoma by remodeling the tumor microenvironment Peng ZhangYi WanChengsheng Zhang Research Open access 13 May 2024 Article: 127
Safety of immune checkpoint inhibitors in patients aged over 80 years: a retrospective cohort study Tatsuki IkomaToshihiko MatsumotoTakayasu Kurata Research Open access 11 May 2024 Article: 126
The efficacy and safety of adding PD-1 blockade to induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) for locoregionally advanced nasopharyngeal carcinoma: an observational, propensity score-matched analysis Ya-Nan JinMeng-Yun QiangJi-Jin Yao Research Open access 11 May 2024 Article: 125
Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study Shengxiang RenAnwen XiongCaicun Zhou Research Open access 10 May 2024 Article: 124
Single-cell sequencing of tumour infiltrating T cells efficiently identifies tumour-specific T cell receptors based on the T cell activation score Chaoting ZhangShance LiZheming Lu Brief Report Open access 10 May 2024 Article: 123
Dual roles of HK3 in regulating the network between tumor cells and tumor-associated macrophages in neuroblastoma Xin WuTao MiDawei He Research Open access 07 May 2024 Article: 122
Integrative analysis of single-cell and bulk RNA sequencing unveils a machine learning-based pan-cancer major histocompatibility complex-related signature for predicting immunotherapy efficacy Jia-Lin FengBo LiangJun Chen Research Open access 07 May 2024 Article: 121
Chemoradiotherapy versus surgery after neoadjuvant chemoimmunotherapy in patients with stage III NSCLC: a real-world multicenter retrospective study Song GuanJifeng SunLujun Zhao Research Open access 07 May 2024 Article: 120
Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer Panpan ZhangZhendong ChenLin Shen Research Open access 07 May 2024 Article: 119
Long-term survival after anti-PD-1 discontinuation in advanced cutaneous squamous cell carcinoma (cSCC): a proof of concept of benefit of concomitant cemiplimab and radiotherapy Barbara Bailly-CailléRomain LevardJean-Matthieu L’Orphelin Brief Report Open access 07 May 2024 Article: 118
Overexpressing S100A9 ameliorates NK cell dysfunction in estrogen receptor-positive breast cancer Yansong LiuMingcui LiFei Ma Research Open access 07 May 2024 Article: 117
Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world data Justin C. MoserShailender BhatiaJeffrey Weber Research Open access 07 May 2024 Article: 116
Extracellular matrix stiffness and tumor-associated macrophage polarization: new fields affecting immune exclusion Ke-Xun YuWei-Jie YuanYong-Xiang Li Review Open access 02 May 2024 Article: 115
Expression patterns of novel immunotherapy targets in intermediate- and high-grade lung neuroendocrine neoplasms Bence FerenczKlára TörökBalázs Döme Research Open access 02 May 2024 Article: 114
Neutrophil-activating secretome characterizes palbociclib-induced senescence of breast cancer cells Gabriele FavarettoMarianna Nicoletta RossiFabrizio Antonangeli Research Open access 02 May 2024 Article: 113
New genetic insights into immunotherapy outcomes in gastric cancer via single-cell RNA sequencing and random forest model Dajun YuJie YangChao Zhu Research Open access 02 May 2024 Article: 112
Clonal expansion of shared T cell receptors reveals the existence of immune commonality among different lesions of synchronous multiple primary lung cancer Yadong WangZhicheng HuangNaixin Liang Research Open access 26 April 2024 Article: 111
